Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban in people with intracranial haemorrhage ID6335 (part review of TA697)

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company • AstraZeneca (andexanet alfa) Patient/carer groups • Arrhythmia Alliance • Atrial Fibrillation Association • Black Health Agency • British Cardiac Patients Association • Cardiovascular Care Partnership (UK) • Circulation Foundation • Different Strokes • HEART UK • Muslim Council of Britain • Pumping Marvellous Foundation • Somerville Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • Thrombosis UK Professional groups • Association of Anaesthetists • Association of Surgeons of Great Britain and Ireland • British Association for Accident and Emergency Medicine • British Association for Immediate Care • British Association of Stroke Physicians • British Cardiovascular Society • British Geriatrics Society • British Trauma Society • British Orthopaedic Association • British Society of Interventional	General • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Possible comparator companies • ADVANZ Pharma (tranexamic acid) • AAH Pharmaceuticals (tranexamic acid) • Accord Healthcare (tranexamic acid) • AMCo (tranexamic acid) • Aurobindo Pharma – Milpharm (tranexamic acid) • Behring UK (prothrombin complex) • Bowmed Ibisqus (tranexamic acid)

Consultees	**Commentators (no right to submit or appeal)**
Radiology • British Society of Neuroradiologists • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Institute of Radiology • British Thoracic Society • British Vein Institute • Clinical Leaders of Thrombosis • College of Paramedics • Royal College of Anaesthetists • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal Pharmaceutical Society • Royal College of Physicians • Royal College of Surgeons • Royal Society of Medicine • Society of British Neurological Surgeons • Society of Cardiothoracic Surgeons • Society for Vascular Technology • Society of Vascular Nurses • St Johns Ambulance • The Intensive Care Society • UK Clinical Pharmacy Association • Vascular Anaesthesia Society of Great Britain and Ireland • Vascular Society of Great Britain and Ireland <u>Others</u> • Department of Health • NHS England • NHS Hounslow CCG • NHS Sutton CCG • Welsh Government	• Mylan (tranexamic acid) • Octapharma (prothrombin complex concentrate) • Pfizer (tranexamic acid) • Rivopharm UK (tranexamic acid) • Sovereign Medical (tranexamic acid) • Takeda (prothrombin complex) • Tillomed Laboratories (tranexamic acid) <u>Other relevant companies</u> • Axunio Pharma (apixaban) • Bayer (rivaroxaban) • Bristol-Myers Squibb (apixaban) • Daiichi Sankyo (edoxaban) • Mylan (apixaban) • Pfizer (apixaban) • Sandoz (apixaban) • Teva (apixaban) <u>Relevant research groups</u> • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research • Thrombosis Research Institute • Trauma Audit Research Network • Wellcome Trust <u>Associated Public Health Groups</u> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed

any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non company consultees are invited to submit statements relevant to the group they are representing.